Is Now a Good Time to Buy Bristol Myers?

Investors knocked Bristol-Myers (BMY) down more than 5% on worries about lackluster results from a mid-stage study, but selling shares may not be the best choice.

May 19, 2014 at 2:30PM

Bristol-Myers (NYSE:BMY) updated investors on its prolific research program for the cancer drug nivolumab this week. The news came in a flurry Wednesday, beginning with a new combination study planned with Celldex, and culminating with updated data for nivolumab in lung and kidney cancer.

Out of all the news, investors seemed to focus on disappointing results from a study combining nivolumab with Bristol's Yervoy, a drug already approved as a treatment for melanoma.

However, that focus may be misplaced given that Bristol continues to push nivolumab forward across a slate of big-market indications.

BMY Chart

BMY data by YCharts

The lung cancer stumble
Patients in the mid-stage study who received both nivolumab and Yervoy saw tumors shrink; however, adverse events occurred in almost half of the patients, causing some to discontinue treatment.

While the data didn't blow analysts away, Bristol remains confident that the combination regimen has merit. Bristol plans to advance the therapy into phase 3 trials later this year.

Growing book of evidence
So far, nivolumab has been highly successful in treating melanoma patients. Updated results in March show that median overall survival was 16.8 months for patients receiving nivolumab, and data released this week shows patients had a 48% survival rate at two years, and 41% survival rate at three years. Those results are pretty impressive considering thatmost patients in the trial had seen cancer progression despite two to five prior treatments.

Nivolumab also has some potential as a third-line non-small cell lung cancer treatment. Previously treated patients receiving nivolumab saw survival rates of 42% at one year, and 24% at two years. That success in tough-to-treat patients has sparked Bristol's plans to file nivolumab for a rolling approval with the FDA by year end.

While results from the nivolumab and Yervoy lung cancer study may not have impressed investors, results from a kidney cancer trial combining the two were solid. Patients' overall response rate to the regimen was between 43% and 48%, and progression-free survival rates ranged between 64% and 65% at 24 weeks.

Nivolumab may also benefit kidney cancer patients when used without Yervoy. In phase 2 trials, overall survival was between 63% and 72% at one year.

Racing to market
Bristol's nivolumab isn't the only promising PD-1 drug currently under development. Merck (NYSE:MRK) is also advancing MK-3475 through the clinic, and will likely beat Bristol to filing for conditional approval in advanced melanoma. During trials, 81% of advanced melanoma patients treated with MK-3475 were alive following 12 months of therapy.

Overall, Merck is studying MK-3475 across eight trials and 3,000 patients as a potential treatment for skin cancer and non-small-cell lung cancer. Those are huge markets that could make MK-3475 a blockbuster, and the FDA's recent granting of priority review for the drug could mean an approval by October. 

Roche(NASDAQOTH:RHHBY) is also working on a PD-L1 therapy, MPDL3280A, which is matching up with its Zelboraf in a phase 1 trial treating advanced melanoma. Zeboraf won FDA approval for advanced melanoma back in 2011 and, if the combination results are strong, Roche thinks sales could head significantly higher than the $400 million Zelboraf registered last year.

In addition to melanoma, Roche is also studying its PD-L1 therapy in bladder cancer, and plans to update investors with data from its early-stage study. Among 20 people treated, half responded to Roche's drug, with average tumor size shrinking by 30%.

Fool-worthy final thoughts
Developing new drugs isn't easy, and developing new cancer drugs is especially difficult. Just 7% of all cancer drugs entering phase 1 ever make it to market. That suggests investors shouldn't be too surprised to see nivolumab come up short somewhere.

A lot of attention will focus on Bristol and Merck's competing PD-1 drugs at ASCO in a few weeks, so investors should stay tuned in to see if more complete data sways opinions. However, given the growing need and significant spending associated with oncology treatment, selling Bristol's shares may not be the right decision for long-term investors.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information